|
1
|
Rieder F and Fiocchi C: Intestinal
fibrosis in IBD-a dynamic, multifactorial process. Nat Rev
Gastroenterol Hepatol. 6:228–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stacey R and Green JT: Radiation-induced
small bowel disease: Latest developments and clinical guidance.
Ther Adv Chronic Dis. 5:15–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamama S, Delanian S, Monceau V and
Vozenin MC: Therapeutic management of intestinal fibrosis induced
by radiation therapy: From molecular profiling to new intervention
strategies et vice et versa. Fibrogenesis Tissue Repair. 5 Suppl
1:S132012.PubMed/NCBI
|
|
4
|
Kendall RT and Feghali-Bostwick CA:
Fibroblasts in fibrosis: Novel roles and mediators. Front
Pharmacol. 5:1232014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeisberg M and Kalluri R: Cellular
mechanisms of tissue fibrosis. 1. Common and organ-specific
mechanisms associated with tissue fibrosis. Am J Physiol Cell
Physiol. 304:C216–C225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Speca S, Giusti I, Rieder F and Latella G:
Cellular and molecular mechanisms of intestinal fibrosis. World J
Gastroenterol. 18:3635–3661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Liu H, Liang Y, Peng P, Ma X and
Zhang X: DKK3 regulates cell proliferation, apoptosis and collagen
synthesis in keloid fibroblasts via TGF-β1/Smad signaling pathway.
Biomed Pharmacother. 91:174–180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conte E, Gili E, Fagone E, Fruciano M,
Iemmolo M and Vancheri C: Effect of pirfenidone on proliferation,
TGF-β-induced myofibroblast differentiation and fibrogenic activity
of primary human lung fibroblasts. Eur J Pharm Sci. 58:13–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abe Y, Murano M, Murano N, Morita E, Inoue
T, Kawakami K, Ishida K, Kuramoto T, Kakimoto K, Okada T, et al:
Simvastatin attenuates intestinal fibrosis independent of the
anti-inflammatory effect by promoting fibroblast/myofibroblast
apoptosis in the regeneration/healing process from TNBS-induced
colitis. Dig Dis Sci. 57:335–344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe
S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al:
Double-blind, placebo-controlled trial of pirfenidone in patients
with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
171:1040–1047. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Sario A, Bendia E, Svegliati Baroni G,
Ridolfi F, Casini A, Ceni E, Saccomanno S, Marzioni M, Trozzi L,
Sterpetti P, et al: Effect of pirfenidone on rat hepatic stellate
cell proliferation and collagen production. J Hepatol. 37:584–591.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miric G, Dallemagne C, Endre Z, Margolin
S, Taylor SM and Brown L: Reversal of cardiac and renal fibrosis by
pirfenidone and spironolactone in streptozotocin-diabetic rat. Br J
Pharmacol. 133:687–694. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu
S and Wei Y: In vitro effects of pirfenidone on cardiac
fibroblasts: Proliferation, myofibroblast differentiation,
migration and cytokine secretion. PLoS One. 6:e281342011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duan L, Qi J, Huang T, Gu X, Xu D, Kong X
and Qian XQ: Pirfenidone attenuates bladder fibrosis and mitigates
deterioration of bladder function in a rat model of partial bladder
outlet obstruction. Mol Med Rep. 12:3639–3647. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin X, Yu M, Wu K, Yuan H and Zhong H:
Effects of pirfenidone on proliferation, migration, and collagen
contraction of human Tenon's fibroblasts in vitro. Invest
Ophthalmol Vis Sci. 50:3763–3770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hewitson TD, Kelynack KJ, Tait MG, Martic
M, Jones CL, Margolin SB and Becker GJ: Pirfenidone reduces in
vitro rat renal fibroblast activation and mitogenesis. J Nephrol.
14:453–460. 2001.PubMed/NCBI
|
|
18
|
Chan AL, Rafii R, Louie S and Albertson
TE: Therapeutic update in idiopathic pulmonary fibrosis. Clin Rev
Allergy Immunol. 44:65–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cottin V: The role of pirfenidone in the
treatment of idiopathic pulmonary fibrosis. Respir Res. 14 Suppl
1:S52013.PubMed/NCBI
|
|
20
|
Takeda Y, Tsujino K, Kijima T and
Kumanogoh A: Efficacy and safety of pirfenidone for idiopathic
pulmonary fibrosis. Patient Prefer Adherence. 8:361–370. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meier R, Lutz C, Cosín-Roger J, Fagagnini
S, Bollmann G, Hünerwadel A, Mamie C, Lang S, Tchouboukov A, Weber
FE, et al: Decreased fibrogenesis after treatment with pirfenidone
in a newly developed mouse model of intestinal fibrosis. Inflamm
Bowel Dis. 22:569–582. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K,
Li R, Li Y, Wu L, Wang G, et al: Oral pirfenidone protects against
fibrosis by inhibiting fibroblast proliferation and TGF-β signaling
in a murine colitis model. Biochem Pharmacol. 117:57–67. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun YW, Zhang YY, Ke XJ, Wu XJ, Chen ZF
and Chi P: Pirfenidone prevents radiation-induced intestinal
fibrosis in rats by inhibiting fibroblast proliferation and
differentiation and suppressing the TGF-β1/Smad/CTGF signaling
pathway. Eur J Pharmacol. 822:199–206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ni BB, Li B, Yang YH, Chen JW, Chen K,
Jiang SD and Jiang LS: The effect of transforming growth factor β1
on the crosstalk between autophagy and apoptosis in the annulus
fibrosus cells under serum deprivation. Cytokine. 70:87–96. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu L, Zhang Q, Mo W, Feng J, Li S, Li J,
Liu T, Xu S, Wang W, Lu X, et al: Quercetin prevents hepatic
fibrosis by inhibiting hepatic stellate cell activation and
reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways. Sci
Rep. 7:92892017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takano M, Yamamoto C, Yamaguchi K, Kawami
M and Yumoto R: Analysis of TGF-β1- and drug-induced
epithelial-mesenchymal transition in cultured alveolar epithelial
cell line RLE/Abca3. Drug Metab Pharmacokinet. 30:111–118. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee BS, Margolin SB and Nowak RA:
Pirfenidone: A novel pharmacological agent that inhibits leiomyoma
cell proliferation and collagen production. J Clin Endocrinol
Metab. 83:219–223. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luna J, Masamunt MC, Lawrance IC and Sans
M: Mesenchymal cell proliferation and programmed cell death: Key
players in fibrogenesis and new targets for therapeutic
intervention. Am J Physiol Gastrointest Liver Physiol.
300:G703–G708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi K, Lee K, Ryu SW, Im M, Kook KH and
Choi C: Pirfenidone inhibits transforming growth factor-β1-induced
fibrogenesis by blocking nuclear translocation of Smads in human
retinal pigment epithelial cell line ARPE-19. Mol Vis.
18:1010–1020. 2012.PubMed/NCBI
|
|
32
|
Downward J: PI 3-kinase, Akt and cell
survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar : PubMed/NCBI
|
